On a blood smear, acute lymphoblastic leukemia (ALL) usually shows lymphoblasts: immature white cells with a large nucleus, fine chromatin, and only a thin rim of blue cytoplasm. The smear often also shows the effects of a crowded bone marrow, with too few red cells, platelets, and neutrophils. A smear strongly suggests ALL, but the diagnosis is confirmed with bone marrow testing, flow cytometry, and genetic studies.
This guide explains what a pathologist or hematologist looks for on the slide, how ALL differs from look-alike conditions, and what happens after the smear raises concern.
What Is Acute Lymphoblastic Leukemia?
ALL is a fast-growing cancer of the lymphoid line of white blood cells. It is one of many hematologic disorders, and it begins when an early lymphoid cell in the bone marrow acquires genetic changes that stop it maturing and let it divide without control.
These abnormal cells, the blasts, fill the marrow and crowd out normal blood production. That is why people with ALL develop anemia, infections, and bleeding. ALL is the most common form of childhood leukemia, with a peak between roughly two and five years of age, but it also occurs in adults. You can read how it compares with other subtypes in our overview of the different types of childhood leukemia.
Causes and risk factors
In most people no single cause is found. Known associations include prior exposure to high-dose radiation or certain chemotherapy drugs, benzene exposure, and inherited conditions such as Down syndrome. Specific genetic changes in the leukemia cells, such as the Philadelphia chromosome formed by a swap between chromosomes 9 and 22, shape how the disease behaves and is treated; see our guide to Philadelphia chromosome-positive acute lymphoblastic leukemia. This subtype is considerably more common in adults than in children.
Symptoms That Lead to a Blood Test
Most symptoms of ALL come from marrow failure or from blasts collecting in other organs. Common features include:
- Tiredness, pallor, and breathlessness from anemia
- Fever and repeated infections from low neutrophils
- Easy bruising, nosebleeds, or tiny red skin spots (petechiae) from low platelets
- Bone pain or limping in children, caused by an expanding marrow
- Swollen lymph nodes, an enlarged liver or spleen, and, in T-cell ALL, sometimes a mass in the chest
These symptoms usually prompt a complete blood count (CBC). When the CBC is abnormal, a blood smear is the natural next step, and it is often where the first real signs of leukemia in blood work are seen.
What the Blood Smear Shows in ALL
A blood smear is made by spreading a drop of blood thinly across a glass slide, staining it (usually with a Wright or May-Grunwald-Giemsa stain), and examining it under the microscope. Unlike an automated counter, a trained eye can judge the shape and maturity of each cell. Our leukemia blood smear guide covers technique in more detail.
The lymphoblast
Typical lymphoblasts are small to medium-sized cells with a very high nucleus-to-cytoplasm ratio. The nucleus is round or slightly folded with finely dispersed chromatin, and nucleoli are small or hard to see. The cytoplasm is scant and pale to moderately blue, and it lacks granules. Crucially, lymphoblasts do not contain Auer rods, the needle-like inclusions that point to acute myeloid leukemia.
The rest of the picture
The background of the smear tells you about the marrow. Red cells are usually normal in size (normocytic) but reduced in number, platelets are sparse, and mature neutrophils are few. The total white count varies widely: it can be very high, normal, or even low. In some patients, few or no blasts circulate at all, so a normal-looking smear does not rule out leukemia when the counts are unexplained.
| Feature | Normal mature lymphocyte | Lymphoblast (ALL) | Myeloblast (AML) |
|---|---|---|---|
| Size | Small | Small to medium | Medium to large |
| Chromatin | Dense, clumped | Fine, dispersed | Fine, dispersed |
| Nucleoli | Not visible | Small or inconspicuous | Often prominent, sometimes several |
| Cytoplasm | Thin rim, pale blue | Scant, no granules | More abundant, may have fine granules |
| Auer rods | Absent | Absent | May be present |
| Myeloperoxidase stain | Negative | Negative | Usually positive |
Appearance alone can be misleading. Reactive lymphocytes in viral infections, such as glandular fever, can look alarming, and some myeloblasts look very similar to lymphoblasts. That is why morphology is always followed by more specific testing.
Confirming the Diagnosis
When the smear suggests ALL, the next steps are designed to confirm the diagnosis, identify the subtype, and assess risk.
- Bone marrow aspirate and biopsy: a sample from the hip bone shows how much of the marrow is replaced by blasts. A diagnosis of acute leukemia generally requires at least 20% blasts in the marrow or blood.
- Flow cytometry (immunophenotyping): antibodies tagged with fluorescent markers identify proteins on the blasts. Markers such as TdT, CD19, CD10, and CD22 point to B-cell ALL, while cytoplasmic CD3 and CD7 point to T-cell ALL.
- Cytogenetics and molecular tests: karyotyping, FISH, and PCR look for changes such as the Philadelphia chromosome (BCR-ABL1), rearrangements of the KMT2A gene, or extra chromosomes (hyperdiploidy), which influence prognosis and treatment.
- Lumbar puncture: examines the spinal fluid for blasts, because ALL can spread to the central nervous system.
Treatment and Monitoring
ALL is treated in phases over a long period, typically two to three years in total.
- Induction: intensive chemotherapy, often including vincristine, a steroid, asparaginase, and sometimes an anthracycline such as doxorubicin, aims to clear blasts and achieve remission.
- Consolidation and intensification: further courses target any leukemia cells that survived induction.
- Maintenance: lower-intensity oral treatment continues for many months to prevent relapse.
- Central nervous system therapy: chemotherapy given into the spinal fluid protects the brain and spinal cord.
Targeted drugs have changed outcomes for particular subgroups. Tyrosine kinase inhibitors are added for Philadelphia-positive disease, and immunotherapies such as blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy are used for B-cell ALL, especially when the disease relapses or is resistant. Stem cell transplant is considered for higher-risk cases.
Once treatment starts, repeated smears and blood counts track recovery. Sensitive measurable residual disease (MRD) tests on marrow samples detect leukemia cells far below what a microscope can see, and MRD results are among the strongest guides to further treatment.
Key Takeaways
- Lymphoblasts on a smear have a high nucleus-to-cytoplasm ratio, fine chromatin, scant agranular cytoplasm, and no Auer rods.
- The smear often shows anemia, low platelets, and few neutrophils, reflecting marrow failure.
- A smear raises suspicion; bone marrow examination, flow cytometry, and genetic testing confirm ALL and define its subtype.
- Treatment is phased over years, and MRD testing guides decisions. More background on related conditions is in our guide to hematological disorders for patients and caregivers.
Frequently Asked Questions
Can a blood smear alone diagnose ALL?
No. A smear can strongly suggest acute leukemia, but it cannot reliably tell ALL apart from AML or reactive conditions. Flow cytometry and bone marrow testing are needed to confirm the diagnosis and determine the subtype.
Can someone have ALL with a normal white blood cell count?
Yes. The white count in ALL can be high, normal, or low, and some patients have few blasts in the blood. Unexplained anemia or low platelets still warrant further investigation even when the white count looks normal.
How are lymphoblasts different from normal lymphocytes?
Normal lymphocytes are small with dense, dark chromatin. Lymphoblasts are often larger, with finer, more open chromatin and a very thin rim of cytoplasm, reflecting their immature state.
Why are smears repeated during treatment?
Repeat smears and counts show whether blasts have cleared from the blood and whether normal cells are recovering. They complement, but do not replace, the more sensitive MRD tests done on bone marrow.
